Navigation Links
Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2011 Results
Date:9/22/2011

790,916)Income tax benefit

--637,391998,408NET LOSS

$  (3,309,229)$ (4,236,381)$(12,815,929)$  (1,792,508)Basic and diluted net loss per common share

$
(0.09)$
(0.40)$
(0.64)$
(0.18)Weighted average number of common shares outstanding used in computing basic and diluted net loss per common share

34,900,59110,722,06120,084,0229,861,215PALATIN TECHNOLOGIES, INC.

and SubsidiaryConsolidated Balance Sheets(unaudited)June 30, 2011June 30, 2010ASSETSCurrent assets:  Cash and cash equivalents$
8,869,639$
5,405,430  Available-for-sale investments-3,462,189  Accounts receivable131,1492,879  Prepaid expenses and other current assets261,947393,313Total current assets19,262,7359,263,811Property and equipment, net1,305,3312,388,365Restricted cash350,000475,000Other assets254,787261,701Total assets$
21,172,853$
2,388,877LIABILITIES AND STOCKHOLDERS' EQUITYCurrent liabilities:  Capital lease obligations$
34,923$
9,670  Accounts payable 496,908155,795  Accrued expenses1,854,0072,219,466  Accrued expenses374,094-  Unearned revenue46,105-Total current liabilities2,806,0372,394,931Capital lease obligations 42,18614,284Deferred rent132,855661,389Total liabilities2,981,0783,070,604Stockholders' equity:  Preferred stock of $0.01 par value – authorized 10,000,000 shares;Series A Convertible; issued and outstanding 4,997 shares as of June 30, 2011 and 2010, respectively5050  Common stock of $0.01 par value – authorized 100,000,000 shares; issued and outstanding 34,900,591 and 11,702,818 shares as of June 30, 2011 and 2010, respectively349,006117,028  Additional paid-in capital239,832,826218,236,723  Accumulated other comprehensive income-138,650  Accumulated deficit (221,990,107)(209,174,178)Total stockholders' equity18,191,7759,318,273Total liabilities and stockholders' equity$
21,172,853$
2,388,877
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Palatin Technologies, Inc. Reports Positive Results of Phase 2a Clinical Study with PL-3994 for the Treatment of Heart Failure
2. Palatin Technologies, Inc. Revised Call-In Number for Teleconference and Webcast to be held on September 30, 2008
3. Palatin Technologies to Report Fiscal Year 2009 First Quarter Results; Conference Call and Webcast on November 17, 2008
4. Palatin Technologies Receives Notification Letter from NYSE Alternext US
5. Palatin Technologies to Report Fiscal Year 2009 Second Quarter Results; Conference Call and Webcast on February 17, 2009
6. Palatin Technologies Listing Compliance Plan Accepted by NYSE Alternext US
7. Palatin Technologies, Inc. Receives U.S. Patent Allowance for Heart Failure Drug Candidate
8. Palatin Technologies, Inc. Reports Positive Bremelanotide Study; Improved Safety Profile with Subcutaneous Administration
9. Palatin Technologies, Inc. to Raise $3.1 Million in Registered Direct Offering
10. Palatin Technologies to Present at the Rodman & Renshaw 11th Annual Global Investment Conference
11. Palatin Technologies, Inc. to Report Fourth Quarter and Fiscal Year 2009 Results; Teleconference and Webcast to be held on September 8, 2009
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... ... July 06, 2015 , ... ... hosted their 2015 bi-annual Pain Management Medical Advisory Board meeting in Palm Springs, ... executive Research and Development team to discuss new clinical practice and research ideas. ...
(Date:7/6/2015)... Research and Markets ... the "Biotechnology for the Non-Biotechnologist" conference ... Non-Biotechnologist, ideal for non-Scientists and Scientists needing to ... of biotechnology. Ideal for Non-Scientists and ... techniques, and potential of biotechnology Why ...
(Date:7/5/2015)... ... 2015 , ... For many years, metal-on-quartz filters were the industry standard for ... a Varian Cary 4000-7000, a Perkin Elmer 800-1100 or a Shimadzu 3600-3700, these filters ... them for their SRM-2031 series going back for many years. Unfortunately, these standards remained ...
(Date:7/3/2015)... ... July 03, 2015 , ... The global failure analysis market is ... to 2020. The bioscience market is expected to grow at the highest CAGR of ... analysis equipment in the research labs and academic institutions for root cause analysis of ...
Breaking Biology Technology:Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 2Proove Biosciences Gathers Key Opinion Leaders in Pain Management for Medical Advisory Board Meeting in Palm Springs, California 3FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 2FireflySci Simplifies the Calibration of UV Spectrophotometers with FUV Photometric Accuracy Standards 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 2Failure Analysis Market to Grow at 7.52% CAGR to 2020 3Failure Analysis Market to Grow at 7.52% CAGR to 2020 4Failure Analysis Market to Grow at 7.52% CAGR to 2020 5
... . , Hydrogen fuel cells will power the automobiles ... being insufficiently competitive. At the University of Houston, Texas, USA, ... new class of electrocatalyst that could help to improve the ... consists of nanoparticles with a platinum-rich shell and a core ...
... $2.25 to $2.35., ST. LOUIS, Oct. 23 , HIGHLIGHTS:, ... periods in 2006):, -- Strongest Quarterly Sales Growth in 2007: ... prior quarters, performance, with reported quarterly growth ... high sales achieved in Q2 2007. Organic ...
... 23 Collagen Matrix, Inc.,announces the launch of ... applications. OssiMend is an all-natural mineral-collagen,composite bone graft ... to fill bony voids or gaps of the ... conformable, non-friable, has a high,absorption capacity, and is ...
Cached Biology Technology:Platinum-rich shell, platinum-poor core 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 2Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 3Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 4Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 5Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 6Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 7Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 8Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 9Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 10Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 11Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 12Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 13Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 14Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 15Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 16Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 17Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 18Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 19Sigma-Aldrich (Nasdaq: SIAL) Q3 2007 Sales Increase 14.0%, Yielding Diluted EPS of $.54. 20Collagen Matrix, Inc. Launches OssiMend(TM) Bone Graft Matrix for Orthopedic and Spine Applications 2
(Date:6/18/2015)... YORK , June 18, 2015 This ... US$ Million by the following Product Segments, which includes ... Systems, Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric ... the US, Canada , ... Asia-Pacific , Latin America ...
(Date:6/17/2015)... Germany , June 17, 2015 ... QIA) today launched new Investigator ® STR assay kits ... the United States . The new genetic fingerprint ... genomic markers (short tandem repeats or STRs) for DNA matching. ... the quality of DNA in each sample, a novel QIAGEN ...
(Date:6/16/2015)... , June 16, 2015 /CNW Telbec/ - ... partnership centralized around the incorporation of handyem,s HPC-150 ... diagnostic laboratory, the Mo-POD™. This unprecedented model of ... International Conference at the Pennsylvania ... from June 15 th to 18 th ...
Breaking Biology News(10 mins):Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 2QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 3QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 4QIAGEN Launches New Genetic Fingerprinting Kits for U.S. Forensic Labs 5handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 2handyem and FlowMetric Diagnostics announce their partnership in the development of Flow Cytometry- Based Solutions in diagnostic capabilities 3
... The National Institute of Neurological Disorders and Stroke (NINDS), a ... new sites as part of the Morris K. Udall Centers ... will provide a five-year investment totaling more than $16 million ... Medical Research in Manhasset, N.Y. NINDS Director ...
... been adjusting to strict new government standards that limit ... to the cover story of the current issue of ... impurities are "genotoxic," capable of damaging the DNA in ... internationally accepted regulations long have limited the levels of ...
... for the world,s plants, conducted by the Royal Botanic Gardens, ... International Union for the Conservation of Nature (IUCN), has revealed ... one in five of the world,s plant species threatened with ... and is the first time that the true extent of ...
Cached Biology News:NINDS awards new Udall Centers for Parkinson's Disease Research 2NINDS awards new Udall Centers for Parkinson's Disease Research 3New study shows over one-fifth of the world's plants are under threat of extinction 2New study shows over one-fifth of the world's plants are under threat of extinction 3New study shows over one-fifth of the world's plants are under threat of extinction 4
VACUGENE PUMP 110V, 1 EA. Category: Nucleid Acid Detection Systems....
Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...
... BMH 71-18 mutS and ES1301 mutS ... coli. Use of these strains prevents repair ... leading to high mutation efficiencies and making ... GeneEditor and Altered Sites II Mutagenesis Systems. ...
propidium iodide *1.0 mg/mL solution in water*...
Biology Products: